In a large observational study, researchers retrospectively evaluated people over 20 years of age with no preexisting dementia who were part of a national health insurance research database in Taiwan
Monoglyceride Lipase (MGL), also referred to as Lysophospholipase-like or Lysophospholipase homolog, plays a crucial role in the endocannabinoid system, where MGL is essential for the degradation of endocannabinoids and the complete hydrolysis of monoglycerides
95% CI, 1.232.44)
In developing regions, this financial barrier is even more pronounced, slowing market penetration despite growing obesity prevalence While efforts are underway to improve affordabilityincluding the introduction of generic formulations and price negotiations in certain marketsthe perception of GLP-1 therapies as premium, high-cost treatments can deter both patients and providers from widespread adoption Overcoming these challenges through the development of cost-effective alternatives, enhanced insurance support, and patient assistance programs will be vital for ensuring sustained and inclusive market growth in the GLP-1 receptor agonists obesity drugs market GLP-1 Receptor Agonists Obesity Drugs Market Scope The market is segmented on the basis of drug type, route of administration, application, and distribution channel
First, it is a potent direct antioxidant capable of neutralizing free radicals including reactive oxygen species (ROS) and reactive nitrogen species